secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001214659-24-012079
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve conversion of Series A Preferred Stock for up to $25M financing
--------------------------------------------------------------------------------

- Proposal approved with 5,356,845 votes for, 79,371 against, 3,043 abstentions; no broker non-votes.
- Conversion relates to Securities Purchase Agreement dated May 8, 2024, for total purchase price up to $25,000,000.
- Approval required under Nasdaq Rule 5635 for issuance exceeding certain share thresholds.
- Special meeting held July 8, 2024; record date May 29, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924012079/0001214659-24-012079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924012079/o782458k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-012079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer